(Q51562990)

7 April 2018

title

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents (English)

1 reference

7 April 2018

1 reference

1 reference

6

J S Harmatz

1 reference

7 April 2018

David J. Greenblatt

2

object named as

D J Greenblatt

1 reference

7 April 2018

Richard I. Shader

7

object named as

R I Shader

1 reference

7 April 2018

Lisa L. von Moltke

1

object named as

L L von Moltke

1 reference

7 April 2018

author name string

J Schmider

3

1 reference

7 April 2018

S X Duan

4

1 reference

7 April 2018

C E Wright

5

1 reference

7 April 2018

publication date

1 September 1996

1 reference

7 April 2018

The Journal of Clinical Pharmacology

published in

1 reference

7 April 2018

volume

36

1 reference

7 April 2018

issue

9

1 reference

7 April 2018

page(s)

783-791

1 reference

7 April 2018

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

1 reference

Midazolam. A review of its pharmacological properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Pharmacokinetics and bioavailability of midazolam in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Midazolam is metabolized by at least three different cytochrome P450 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

A potentially hazardous interaction between erythromycin and midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Rifampin drastically reduces plasma concentrations and effects of oral midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Dose dependent pharmacokinetics of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Interaction between grapefruit juice and midazolam in humans*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Clinical pharmacokinetics of fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB04251.X

10.1002/J.1552-4604.1996.TB04251.X

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018